Zynex (ZYXIQ) ROCE %: 0.00% (As of Sep. 2025)


What is Zynex ROCE %?

Zynex ZYXIQ ROCE % is 0.00% as of Sep. 2025. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zynex's annualized ROCE % for the quarter that ended in Sep. 2025 was 0.00%.

Zynex  (OTCPK:ZYXIQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zynex ROCE % Related Terms

Zynex ROCE % Historical Data

* Premium members only.

The historical data trend for Zynex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zynex ROCE % Chart

Zynex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.90 25.94 22.00 12.79 5.38

Zynex Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.49 -2.13 -53.83 -81.03 0.00

Zynex ROCE % Calculation

Zynex's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=6.009/( ( (136.904 - 18.532) + (122.079 - 16.864) )/ 2 )
=6.009/( (118.372+105.215)/ 2 )
=6.009/111.7935
=5.38 %

Zynex's ROCE % of for the quarter that ended in Sep. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2025 )  (Q: Jun. 2025 )(Q: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2025 )  (Q: Jun. 2025 )(Q: Sep. 2025 )
=-175.848/( ( (85.935 - 73.859) + (45.322 - 78.846) )/ 2 )
=-175.848/( ( 12.076 + -33.524 )/ 2 )
=-175.848/-10.724
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Zynex (ZYXIQ) has a ROCE % of 0.00% as of Sep. 2025.
Is Zynex's ROCE % too high?
Zynex's current ROCE % is 0.00%.
How does Zynex's ROCE % compare to MCK and COR?
Zynex's ROCE % of 0.00% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zynex's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zynex stock overvalued right now?
Zynex (ZYXIQ) has a current ROCE % of 0.00%. The stock's GF Value™ is $5.54, compared to a current price of $0.06 — trading 99% below its estimated fair value. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zynex (ZYXIQ), the current ROCE % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zynex Business Description

Address 9555 Maroon Circle, Englewood, CO, USA, 80112
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.